Table 4 E. coli antibiotic resistance rate in patients with COVID-19
Antibiotic | Susceptible | Intermediate | Resistance | |||
|---|---|---|---|---|---|---|
No | % | No | % | No | % | |
AMP | 0 | 0 | 0 | 0 | 50 | 100 |
AMX-C | 11 | 22.0 | 9 | 18.0 | 30 | 60.0 |
Piperacillin/tazobactam | 31 | 62.0 | 8 | 16.0 | 11 | 22.0 |
AMK | 31 | 62.0 | 3 | 6.0 | 16 | 32.0 |
GEN | 32 | 64.0 | 3 | 6.0 | 15 | 30.0 |
MEM | 43 | 86.0 | 5 | 10.0 | 2 | 4.0 |
IPM | 44 | 88.0 | 4 | 8.0 | 2 | 4.0 |
ETP | 46 | 92.0 | 1 | 2.0 | 3 | 6.0 |
CIP | 35 | 70.0 | 9 | 18.0 | 6 | 12.0 |
LEV | 38 | 76.0 | 4 | 8.0 | 8 | 16.0 |
TG | 40 | 80.0 | 2 | 4.0 | 8 | 16.0 |
Trimethoprim/sulfamethoxazole | 28 | 56.0 | 2 | 4.0 | 20 | 40.0 |
Ceftazidime | 25 | 50.0 | 3 | 6.0 | 22 | 44.0 |
CFP | 18 | 36.0 | 1 | 2.0 | 31 | 62.0 |
CFN | 18 | 36.0 | 3 | 6.0 | 29 | 58.0 |
CXM | 17 | 34.0 | 3 | 6.0 | 30 | 60.0 |
CFX | 15 | 30.0 | 4 | 8.0 | 31 | 62.0 |